FGF-2 targets sclerostin in bone and myostatin in skeletal muscle to mitigate the deleterious effects of glucocorticoid on musculoskeletal degradation
Authors:
- 1 July 2019
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 229, 261-276
Abstract
No abstract availableKeywords
Funding Information
- University Grants Commission
- Central Mechanical Engineering Research Institute, Council of Scientific and Industrial Research
This publication has 59 references indexed in Scilit:
- Muscle–bone interactions: basic and clinical aspectsEndocrine, 2013
- Cellular and molecular mechanisms of muscle atrophyDisease Models & Mechanisms, 2013
- Selective glucocorticoid receptor modulation maintains bone mineral density in miceJournal of Bone and Mineral Research, 2012
- The skeletal muscle secretome: an emerging player in muscle–bone crosstalkBoneKEy Reports, 2012
- Fibroblast Growth Factor 2 Stimulation of Osteoblast Differentiation and Bone Formation Is Mediated by Modulation of the Wnt Signaling PathwayJournal of Biological Chemistry, 2011
- Advances in Glucocorticoid-Induced OsteoporosisCurrent Rheumatology Reports, 2011
- Endogenous FGF‐2 is critically important in PTH anabolic effects on boneJournal of Cellular Physiology, 2008
- Glucocorticoid‐induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralizationArthritis & Rheumatism, 2008
- Mechanisms of glucocorticoid-induced myopathyJournal of Endocrinology, 2008
- Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblastsBiochemical and Biophysical Research Communications, 2005